PVCT Provectus Biopharmaceuticals - Uveal Melanoma Background - PVCT Provectus Biopharmaceuticals - InvestorVillage
PVCT Provectus Biopharmaceuticals

  • Investor Village needs your help. We are working hard to improve your user experience
    by upgrading the site so it works better on the latest mobile devices, browsers, O/S, etc. Because costs exceed our normal operating budget, we are asking everyone, including "lurkers," to support our efforts.

    Click this PayPal link to make a one-time contribution in whatever amount you think is fair.

    Or click here to support us with a monthly contribution, starting as low as $2.50 per month.

    Payments can be made directly via PayPal or Credit Card with no need to create an Investor Village account. Cancel any time.

This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4316 of 4716  at  7/11/2019 9:21:26 AM  by

Desmo


Uveal Melanoma Background

Maybe info on UM has been posted here before, but I came across this abstract and found it a helpful background read.
Link to source here.  

 

Uveal melanoma: relatively rare but deadly cancer

Eye volume 31, pages 241257 (2017) 

Although it is a relatively rare disease, primarily found in the Caucasian population, uveal melanoma is the most common primary intraocular tumor in adults with a mean age-adjusted incidence of 5.1 cases per million per year. Tumors are located either in iris (4%), ciliary body (6%), or choroid (90%). The host susceptibility factors for uveal melanoma include fair skin, light eye color, inability to tan, ocular or oculodermal melanocytosis, cutaneous or iris or choroidal nevus, and BRCA1-associated protein 1 mutation. Currently, the most widely used first-line treatment options for this malignancy are resection, radiation therapy, and enucleation. There are two main types of radiation therapy: plaque brachytherapy (iodine-125, ruthenium-106, or palladium-103, or cobalt-60) and teletherapy (proton beam, helium ion, or stereotactic radiosurgery using cyber knife, gamma knife, or linear accelerator). The alternative to radiation is enucleation. Although these therapies achieve satisfactory local disease control, long-term survival rate for patients with uveal melanoma remains guarded, with risk for liver metastasis. There have been advances in early diagnosis over the past few years, and with the hope survival rates could improve as smaller tumors are treated. As in many other cancer indications, both early detection and early treatment could be critical for a positive long-term survival outcome in uveal melanoma. These observations call attention to an unmet medical need for the early treatment of small melanocytic lesions or small melanomas in the eye to achieve local disease control and vision preservation with the possibility to prevent metastases and improve overall patient survival. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 180
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...